Quinazoline

Quinazoline

SCHEMBL3259190

c1ccc2[nH]ccc2c1.c1ccc2ncncc2c1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.67
TRPA1 O75762 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
ITGB2 P05107 1/20 0.57
ICAM1 P05362 1/20 0.57
ITGAL P20701 1/20 0.57
CA4 P22748 1/20 0.57
CA6 P23280 1/20 0.57
AHR P35869 1/20 0.57
ADK P55263 1/20 0.57
PIK3CD O00329 1/20 0.46
PIK3CA P42336 1/20 0.46
TDO2 P48775 2/20 0.46
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinazoline SCHEMBL29356169 0.82 EGFR (1.00) EGFRPIK3CDPIK3CATDO2PDGFRB
Quinazoline SCHEMBL22833783 0.82 EGFR (1.00) EGFRPIK3CDPIK3CATDO2PDGFRB
Quinazoline SCHEMBL29490398 0.82 EGFR (1.00) EGFRPIK3CDPIK3CATDO2PDGFRB
Quinazoline SCHEMBL5920 0.82 EGFR (1.00) EGFRPIK3CDPIK3CATDO2PDGFRB
Quinazoline SCHEMBL11972093 0.80 EGFR (0.67) EGFRPIK3CDPIK3CATDO2PDGFRB
SCHEMBL3196932 0.80 EGFR (0.95) EGFRPIK3CDPIK3CATDO2PDGFRB
Quinazoline SCHEMBL3533306 0.80 EGFR (0.95) EGFRPIK3CDPIK3CATDO2PDGFRB
Quinazoline SCHEMBL1119374 0.80 EGFR (0.95) EGFRPIK3CDPIK3CATDO2PDGFRB
Quinazoline SCHEMBL21055790 0.80 EGFR (0.95) EGFRPIK3CDPIK3CATDO2PDGFRB
Quinazoline SCHEMBL4487630 0.80 EGFR (0.95) EGFRPIK3CDPIK3CATDO2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112778312-B Organic material containing indoloquinazolinedione heterocyclic structure and application thereof 北京燕化集联光电技术有限公司 2022-12-02 CN claimed
CN-109136319-B Method for improving microbial production of indole quinazoline active alkaloid compound and application 中山大学 2021-07-13 CN claimed
CN-112778312-A Organic material containing indoloquinazolinedione heterocyclic structure and application thereof 北京燕化集联光电技术有限公司 2021-05-11 CN claimed
CN-109136319-A A kind of method and application for improving microorganism and producing indole quinazoline class active bio alkali cpd 中山大学 2019-01-04 CN claimed
CN-103288827-B A kind of preparation method and activity of new indole quinazoline Alkaloid INSTITUTE OF BOTANY,JIANGSU PROVINCE AND CHINESE ACADEMY OF SCIENCES (CN) 2016-05-25 CN claimed
US-20140037561-A1 COMPOSITION AND METHODS OF ENHANCED SKIN CELL TURNOVER RUKU HOLDINGS, LLC 2014-02-06 US claimed
CN-103288827-A Preparation method and activity of novel indole quinazoline alkaloid INST BOTANY JIANGSU PROVINCE & CAS 2013-09-11 CN claimed
WO-2012105982-A1 SKIN RENEWAL ENHANCER KULESZA JOHN E (US) 2012-08-09 WO claimed
CN-102399221-A Application of diindoloquinazoline alkaloid in preparation of antitumor drugs and antifungal drugs INST BOTANY JIANGSU PROVINCE & CAS 2012-04-04 CN claimed
CN-102093357-A Novel indoletriazole alkaloid as well as preparation method and antifungal application thereof INST BOTANY JIANGSU PROVINCE & CAS 2011-06-15 CN claimed
US-7655659-B2 Biomimetic of Evodia rutaecarpa fruit extract for amelioration of inflammation APPLIED GENETICS INCORPORATED DERMATICS (US) 2010-02-02 US claimed
US-20080096902-A1 Biomimetic Of Evodia Rutaecarpa Fruit Extract For Amelioration Of Inflammation APPLIED GENETICS INCORPORATED DERMATICS (US) 2008-04-24 US claimed
CN-101005856-A Biomimetic of evodia rutaecarpa fruit extract for amelioration of inflammation APPLIED GENETICS INC DERMATICS (US) 2007-07-25 CN claimed
EP-1784225-A2 BIOMIMETIC OF EVODIA RUTAECARPA FRUIT EXTRACT FOR AMELIORATION OF INFLAMMATION Applied Genetics Incorporated Dermatics (US) 2007-05-16 EP claimed
WO-2006023377-A2 BIOMIMETIC OF EVODIA RUTAECARPA FRUIT EXTRACT FOR AMELIORATION OF INFLAMMATION APPLIED GENETICS INCORPORATED DERMATICS (US) 2006-03-02 WO claimed
CN-117257808-B Application of rutaecarpine in preparation of product for promoting wound healing 广州市朝利良生物科技有限公司 2024-02-20 CN disclosed
CN-117257808-A Application of rutaecarpine in preparation of product for promoting wound healing 广州市朝利良生物科技有限公司 2023-12-22 CN disclosed
US-20030082631-A1 Compounds modulating PPAR-gamma BIOVITRUM AB (SE) 2003-05-01 US disclosed
US-20030073862-A1 Compounds BIOVITRUM AB (SE) 2003-04-17 US disclosed
WO-2003004458-A1 NEW COMPOUNDS BIOVITRUM AB (SE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082631-A1 Compounds modulating PPAR-gamma PPARG, PPARA, PPARD EGFR 863/4885TRPA1 740/4885CA1 4735/4885
US-20030073862-A1 Compounds PPARG, PPARA, PPARD EGFR 1207/4885TRPA1 929/4885CA1 4822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.